Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C19H22N2O.H2O4S |
| Molecular Weight | 686.86 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C3=C4C=CC=CC4=NC=C3.[H][C@@]5(C[C@@H]6CC[N@]5C[C@@H]6C=C)[C@@H](O)C7=C8C=CC=CC8=NC=C7
InChI
InChIKey=WBBHOISPYYYBTC-SJFRDBBCSA-N
InChI=1S/2C19H22N2O.H2O4S/c2*1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17;1-5(2,3)4/h2*2-7,9,13-14,18-19,22H,1,8,10-12H2;(H2,1,2,3,4)/t2*13-,14-,18+,19-;/m00./s1
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H22N2O |
| Molecular Weight | 294.3908 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22512909 |
https://www.ncbi.nlm.nih.gov/pubmed/20768740
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22512909 |
https://www.ncbi.nlm.nih.gov/pubmed/20768740
Cinchonine is cinchona bark alkaloid, which was used to treat malaria. Cinchonine is more efficient than quinine in increasing the intracellular accumulation and restoring the cytotoxicity of doxorubicin, mitoxantrone and vincristine on well-characterized multidrug resistance (MDR) cell lines. In the phase I of clinical trial was investigated the properties of cinchonine combined with the CHVP (cyclophosphamide, doxorubicin, vinblastine, methylprednisolone) regimen in relapsed and refractory lymphoproliferative syndromes.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4302 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2120 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1298088 |
200 mg 3 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: QUININE |
CINCHONINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
420 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1298088 |
133 mg 3 times / day multiple, intravenous dose: 133 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: QUININE |
CINCHONINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
20 mg/kg 1 times / 4 weeks other, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
22.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
15 mg/kg 1 times / 4 weeks other, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
23.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
30 mg/kg 1 times / 4 weeks other, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
29.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
25 mg/kg 1 times / 4 weeks other, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
35.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
35 mg/kg 1 times / 4 weeks other, intravenous dose: 35 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1298088 |
133 mg 3 times / day multiple, intravenous dose: 133 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: QUININE |
CINCHONINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.41 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
20 mg/kg 1 times / 4 weeks other, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.98 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
15 mg/kg 1 times / 4 weeks other, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.65 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
30 mg/kg 1 times / 4 weeks other, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
25 mg/kg 1 times / 4 weeks other, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: DOXORUBICIN |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11187897 |
35 mg/kg 1 times / 4 weeks other, intravenous dose: 35 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
CINCHONINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16695641 |
3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered: |
CINCHONINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb |
|
| The enantioselective synthesis of alpha-amino acid derivatives via organoboranes. | 2002 Aug 14 |
|
| Catalytic enantioselective fluorination of beta-keto esters by phase-transfer catalysis using chiral quaternary ammonium salts. | 2002 Feb 21 |
|
| A selective PVC membrane for di- or trinitrophenol based on N,N-dibenzyl-3,3',5,5'-tetramethylbenzidine. | 2002 Jan |
|
| New crystalline complex of quinine and quinidine. | 2002 Nov-Dec |
|
| Cobalt complex of cinchonine: intermolecular interactions in two crystalline modifications. | 2002 Nov-Dec |
|
| Hydrogenation of cinchona alkaloids over supported Pt catalyst. | 2003 |
|
| The characterisation of supported platinum nanoparticles on carbon used for enantioselective hydrogenation: a combined electrochemical-STM approach. | 2003 Feb 17 |
|
| Preparation of enantiopure 1-azabicyclo[3.2.2]nonanes functionalized at carbon C3, from cinchonine and cinchonidine. stereoselective solvolysis and an easily enolizable ketone. | 2003 Jun 13 |
|
| Acyclic stereoselective boron alkylation reactions for the asymmetric synthesis of beta-substituted alpha-amino acid derivatives. | 2003 Mar 5 |
|
| The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids. | 2003 Sep 1 |
|
| Short columns with molecularly imprinted monolithic stationary phases for rapid separation of diastereomers and enantiomers. | 2004 May 5 |
|
| Role of the solvent in the adsorption-desorption equilibrium of cinchona alkaloids between solution and a platinum surface: correlations among solvent polarity, cinchona solubility, and catalytic performance. | 2005 Jan 13 |
|
| Bioactive cinchona alkaloids from Remijia peruviana. | 2005 Mar 23 |
|
| Michael addition of thiols to alpha-enones in ionic liquids with and without organocatalysts. | 2006 Apr 7 |
|
| Highly enantioselective cyanation of aldehydes catalyzed by a multicomponent titanium complex. | 2006 Jul 21 |
|
| Time-lapse STM studies of diastereomeric cinchona alkaloids on platinum metals. | 2006 Nov 2 |
|
| Highly enantioselective direct aldol reaction catalyzed by cinchona derived primary amines. | 2007 Sep 21 |
|
| Temperature-dependent time-resolved fluorescence study of cinchonine alkaloid dication. | 2008 Jan |
|
| Resolution of (+)-cinchonine and (-)-cinchonidine by phase-modulation fluorescence spectroscopy. | 2009 Apr 20 |
|
| Metal complexes of cinchonine as chiral building blocks: a strategy for the construction of nanotubular architectures and helical coordination polymers. | 2009 Apr 22 |
|
| Influence of peripheral groups on the physical and chemical behavior of cinchona alkaloids. | 2009 Aug 27 |
|
| Empire and alternatives: Swietenia febrifuga and the Cinchona substitutes. | 2010 Jan |
|
| Self-association promoted conformational transition of (3R,4S,8R,9R)-9-[(3,5-bis(trifluoromethyl)phenyl))-thiourea](9-deoxy)-epi-cinchonine. | 2010 Jan |
|
| Channel-like crystal structure of cinchoninium L-O-phosphoserine salt dihydrate. | 2010 Jun |
|
| Monodispersed, molecularly imprinted polymers for cinchonidine by precipitation polymerization. | 2010 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/20769234 | https://www.ncbi.nlm.nih.gov/pubmed/3321829
relapsed and refractory lymphoproliferative syndromes: Cinchonine dihydrochloride was given as a continuous i.v. infusion from day 1 to day 3, over a 48-h period. The first dose level was 15 mg/kg/d. The following steps were defined by a 5 mg/kg/d increase of cinchonine dose over the previous step.
malaria: it was injected 7(1/2) grains of cinichonine bihydrochloride into the deltoid muscle on the day before an attack was due, and warned the patient that this could not be expected to stop completely the attack due the next day
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:16 UTC 2023
by
admin
on
Fri Dec 15 15:01:16 UTC 2023
|
| Record UNII |
342JR840KF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C271
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11948449
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
100000080091
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
227-708-4
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
342JR840KF
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
CHEMBL588619
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
DTXSID80974891
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
5949-16-6
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
C75266
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY | |||
|
SUB13376MIG
Created by
admin on Fri Dec 15 15:01:16 UTC 2023 , Edited by admin on Fri Dec 15 15:01:16 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |